Latest news with #Shield™
Yahoo
25-03-2025
- Health
- Yahoo
Guardant Health's Shield Blood Test Now Covered for VA Community Care Beneficiaries
US veterans and eligible family members now have access to blood test for colorectal cancer screening with no copay Benefit will cover all eligible individuals ages 45-84, representing first coverage beyond Medicare population for Shield PALO ALTO, Calif., March 25, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered by a key healthcare insurance program for U.S. veterans. The screening test is covered for patients receiving community care authorized by the U.S. Department of Veterans Affairs (VA) as an in-network benefit, with no copay for average-risk individuals who are age 45 or older. Following Medicare coverage for Shield in August 2024, the VA network coverage is the first for individuals between the ages of 45 and 64. The U.S. Department of Veterans Affairs (VA) Community Care Network (CCN) consists of community-based practitioners who provide veterans with healthcare services and covers approximately 9.1 million beneficiaries.1 "We are proud of the lifesaving value that the Shield blood test can bring to U.S. veterans and their families," said AmirAli Talasaz, Guardant Health co-CEO. "This coverage decision by the VA is the first for younger and non-Medicare beneficiaries and we are excited to broaden the impact of our screening test to help detect more colorectal cancer early, when it is most treatable." The U.S. Food and Drug Administration (FDA) approved Shield in July 2024 as the first blood test for primary CRC screening, and the Centers for Medicare & Medicaid Services (CMS) recently approved Advanced Diagnostic Laboratory Test (ADLT) status for Shield for colorectal cancer screening. The Shield blood test is FDA approved for primary non-invasive screening for colorectal cancer in average-risk individuals age 45 and older and can be ordered by any prescribing healthcare provider. For more information, visit About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Guardant Health Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. References1. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Michael Weistpress@ +1 317-371-0035
Yahoo
05-03-2025
- Health
- Yahoo
Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities
Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana PALO ALTO, Calif., March 05, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. Nationwide, colorectal cancer is the second leading cause of cancer-related death, even though it is highly treatable when detected in early stages. An estimated 53,000 people in the U.S. died from the disease in 2024. Northern Louisiana has a particularly high colorectal cancer incidence rate, being home to 7 of the 11 highest prevalence areas in the state. Colon cancer is also more prevalent in African American populations, which represent 59% of Partners in Wellness patients. Based out of Shreveport, Louisiana, Partners in Wellness brings mobile screening vans to more than 30 communities in northern and central Louisiana and offers critical cancer screenings that are open to everyone—regardless of insurance status or ability to pay. As a result of a generous gift from Dak Prescott's Faith Fight Finish Foundation, the program's vans will now offer the Shield blood test so that individuals can be screened for colon and rectal cancer with a simple blood draw taken right on the mobile unit. Colon cancer is one of four pillars of the foundation, in tribute to Prescott's mother, Margaret "Peggy" Prescott, who passed away in 2013 at the age of 52 after a courageous battle with Stage 4 colon cancer. "Detecting colon cancer early—when it's treatable—can make all the difference in the outcome," said Prescott. "And now screening can be as simple and convenient as having your blood drawn. I'm grateful to be able to join forces with Guardant Health and Partners in Wellness to give more people in my home state of Louisiana the chance to complete their screening with a simple blood test, so they can have more time down the road to spend with family and friends." Since 1999, the Partners in Wellness mobile cancer screening program has served more than 20,000 patients and provided more than 50,000 screenings at no cost to patients. "Screening for early detection of colorectal cancer is critical in Louisiana, especially northern Louisiana, because this region has significantly higher occurrence and mortality rates from the disease than other parts of the country," said Dr. Richard Mansour, Interim Director of Feist-Weiller Cancer Center. "We're grateful for the way Dak is making it possible for so many people in our underserved communities to be screened much earlier for colon cancer." Screening events during Colorectal Cancer Awareness Month Partners in Wellness will be holding multiple mobile screening events during the month of March (Colorectal Cancer Awareness Month). Community members eligible for colorectal cancer screening will be able to receive a Shield blood test at these events regardless of their insurance status or ability to pay. Results of the test are available in about two weeks. For more information about a screening event near you or to make an appointment, contact Partners in Wellness at 1-800-582-4523 or visit their website. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. About Ochsner LSU Health Shreveport—Feist-Weiller Cancer Center Ochsner LSU Health Shreveport – Feist-Weiller Cancer Center brings together specialists from many fields to provide outstanding cancer care to the people of north Louisiana and the surrounding region. In addition to providing comprehensive, multidisciplinary cancer care, Feist-Weiller Cancer Center (FWCC) gives patients access to national cancer clinical trials. Collaboration between cancer researchers and treating physicians fosters a better understanding of cancer and leads to life-saving research breakthroughs. FWCC is also educating future leading oncologists through LSU Health Shreveport's Hematology/Oncology Fellowship Program. As a designated Center of Excellence in Cancer Research, Treatment, and Education, Feist-Weiller Cancer Center offers preeminent care and services to patients across the region. Guardant Health Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. View source version on Contacts Guardant Health Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Michael Weistpress@ +1 317-371-0035 Partners in Wellness Contacts Laurie Priftislpriftis@ 318-861-0855
Mid East Info
31-01-2025
- Business
- Mid East Info
M42 and Hikma sign strategic MOU to enhance preventive and predictive cancer care in the UAE - Middle East Business News and Information
M42, a global health leader powered by artificial intelligence (AI), and Hikma Pharmaceuticals PLC (Hikma), announced the signing of a strategic memorandum of understanding (MOU), to accelerate the implementation of more precise, preventive and predictive cancer care programmes, utilising cutting-edge genomics screening technology. Under this agreement, Hikma and M42 will enhance their collaboration to promote the use of Shield™, a non-invasive laboratory-developed test (LDT) by Guardant Health Inc., for colorectal cancer (CRC) screening, aiming to improve screening adherence rates in the UAE. Shield™ is the first blood test to be approved by the US FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield in a manner similar to all other non-invasive methods recommended in screening guidelines. Dr. Fahed Al Marzooqi, Chief Executive Officer, Integrated Health Solutions, M42, said: 'At M42, we are committed to harnessing cutting-edge technologies to improve patient outcomes and empower health systems to deliver proactive care. This collaboration with Hikma reflects our dedication to supporting Abu Dhabi's broader efforts to lead in next-generation screening and health innovation. By integrating AI and genomics-driven solutions, we are redefining traditional healthcare models to create a healthier, more sustainable future for all.' Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: ' We are proud to sign this strategic partnership with M42 – a company that shares our commitment to innovation shaping the future of healthcare to improve patient outcomes. This important endeavour is focused on enhancing early disease detection, enabling more precise diagnoses, and facilitating more effective treatments, particularly in oncology and preventive care, which is aligned with our ambition of providing broader healthcare solutions focused on precision medicine.' Last year Hikma announced that it had signed an exclusive agreement with Guardant Health, Inc. for the commercialisation and marketing of Guardant Health's portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumour mutation profiling across all solid cancers in the Middle East and North Africa (MENA). The agreement includes tests such as the US FDA approved Shield™ for colorectal cancer screening and early detection, as well as Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers. The introduction of the Shield™ test for colorectal cancer screening marks a transformative step in advancing precision and preventive healthcare across the region.
Zawya
30-01-2025
- Health
- Zawya
Hikma and M42 sign strategic MoU to advance healthcare innovation in the UAE
Dubai, United Arab Emirates – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has signed a strategic memorandum of understanding (MOU) with M42, a global health leader powered by artificial intelligence (AI) and technology, to advance healthcare innovation in the United Arab Emirates (UAE) in the fight against colorectal cancer. The MOU was signed on the sidelines of the Arab Health 2025 conference and aims to accelerate the implementation of more precise, preventive and predictive cancer care programmes, utilising cutting-edge genomics screening technology. Under this agreement, Hikma and M42 will enhance their collaboration to promote the use of Shield™, a non-invasive laboratory-developed test (LDT) by Guardant Health Inc., for colorectal cancer (CRC) screening, aiming to improve screening adherence rates in the UAE. Shield™ is the first blood test to be approved by the US FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield in a manner similar to all other non-invasive methods recommended in screening guidelines. The Abu Dhabi Public Health Centre (ADPHC), in partnership with M42, recently introduced the non-invasive blood-based liquid biopsy test Shield™ for colorectal cancer screening as part of the IFHAS comprehensive health screening programme. Shield™ is already available for screening at key healthcare centres and M42 locations across Abu Dhabi, Al Ain and the Al Dhafra region. Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: ' We are proud to sign this strategic partnership with M42 – a company that shares our commitment to innovation shaping the future of healthcare to improve patient outcomes. This important endeavour is focused on enhancing early disease detection, enabling more precise diagnoses, and facilitating more effective treatments, particularly in oncology and preventive care, which is aligned with our ambition of providing broader healthcare solutions focused on precision medicine.' Dr. Fahed Al Marzooqi, Chief Executive Officer, Integrated Health Solutions, M42, said: 'At M42, we are committed to harnessing cutting-edge technologies to improve patient outcomes and empower health systems to deliver proactive care. This collaboration with Hikma reflects our dedication to supporting Abu Dhabi's broader efforts to lead in next-generation screening and health innovation. By integrating AI and genomics-driven solutions, we are redefining traditional healthcare models to create a healthier, more sustainable future for all.' Last year Hikma announced that it had signed an exclusive agreement with Guardant Health, Inc. for the commercialisation and marketing of Guardant Health's portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumour mutation profiling across all solid cancers in the Middle East and North Africa (MENA). The agreement includes tests such as the US FDA approved Shield™ for colorectal cancer screening and early detection, as well as Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers. The introduction of the Shield™ test for colorectal cancer screening marks a transformative step in advancing precision and preventive healthcare across the region. About Hikma For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, MENA and Europe. For more information, please visit: *Source: AETOSWire Contacts: Enquiries: Bedour Mossa Senior PR Account Manager APCO bmossa@
Associated Press
30-01-2025
- Health
- Associated Press
Guardant Health's Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an agreement with the Abu Dhabi Public Health Center (ADPHC) to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant's Shield™ test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational pharmaceutical group and regional partner for Guardant in the Middle East and North Africa, and will be administered by the M42 healthcare system. 1 Colorectal cancer is the third most common type of cancer in Abu Dhabi, with 63% of cases diagnosed at a late stage, which adversely affects health outcomes and lowers survival rates. 2 The introduction of the Shield blood test is intended to be a significant step forward in improving screening participation, early detection and outcomes for the community. The Shield test will be provided as part of the ADPHC's IFHAS comprehensive health screening program and will be available at major healthcare facilities operated by Ambulatory Healthcare Services and M42 sites across Abu Dhabi, Al Ain, and the Al Dhafra region. This broad accessibility and the more pleasant screening experience are expected to address low adherence rates, a key challenge in the early detection of colorectal cancer. 'Early detection of colorectal cancer can dramatically improve survival rates,' said AmirAli Talasaz, Guardant Health co-CEO. 'This new population screening program by the Department of Health in Abu Dhabi prioritizes community health by providing a more pleasant screening option that can help increase early detection and improve outcomes for the people of the UAE.' The blood-based colorectal cancer screening program is expected to screen approximately 10,000 people across Abu Dhabi and surrounding regions in its first year. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. Zarak Khurshid [email protected] Contact: Michael Weist [email protected] +1 317-371-0035 SOURCE: Guardant Health, Inc. Copyright Business Wire 2025. PUB: 01/30/2025 08:05 AM/DISC: 01/30/2025 08:05 AM
